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ABSTRACT
Introduction: Povidone iodine (PVP-I) 10%
aqueous solution is a commonly utilized
anti-septic employed for sterilization of the
ocular surface prior to interventional
procedures. Dimethylsulfoxide (DMSO) is a
well-known skin penetration agent scarcely
utilized in ophthalmic drug formulations. We
describe here a low-dose formulation of 1%
PVP-I (w/w) in a gel containing DMSO for use in
the setting of recalcitrant rosacea
blepharoconjunctivitis. A review of the ocular
uses of dimethylsulfoxide is also presented.
Case report: A 78-year-old male presented with
chronic, long-standing blepharitis involving
both the anterior and posterior lid margins.
Posterior lid and skin inflammatory changes
were consistent with ocular rosacea. Previous
oral and topical therapies had been largely
ineffective at controlling his condition.
Conclusion: The topical PVP-I/DMSO system
was effective in abating the signs and
symptoms of rosacea blepharoconjunctivitis.
Further investigation of this novel agent is
warranted.
Keywords: Blepharitis; Rosacea; Conjunctivitis;
Povidone iodine; Dimethylsulfoxide
INTRODUCTION
Blepharitis is a common ocular condition
presenting in a large percentage of the
population [1, 2]. For most sufferers profound
visual impairment is rare, however, a majority
will demonstrate chronic ocular surface
dysfunction including evaporative dry eye [3].
There are a variety of causal factors implicated
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in blepharitis including bacterial overgrowth,
yeast colonization, viral infection, Demodex
mites, atopy, seborrhea, environmental factors,
hormonal dysregulation, and rosacea [4].
Rosacea is a chronic inflammatory skin
condition with multiple, distinct subtypes that
affects approximately 16 million Americans [5].
Transient and nontransient facial flushing,
telangiectasia, and inflammatory papules and
pustules represent the most commonly
recognized skin manifestations [5].
To more accurately diagnose and treat
blepharitis, the disease is frequently
subdivided based on anatomical position.
Anterior blepharitis is frequently associated
with Gram-positive bacterial overgrowth or
seborrhea [6]. Common findings include eyelid
erythema, scurf, collarettes, lid margin
thickening or tylosis ciliaris, and breakage or
misdirection of cilia. Posterior blepharitis most
commonly manifests as meibomian gland
dysfunction with other findings that may
include lid erythema, telangiectatic lid margin
vasculature, hyperkeratosis, chalazia, and tarsal
inflammation.
It is largely recognized that a spectrum of
meibomian gland dysfunction exists in those
patients suffering from chronic posterior
blepharitis [7]. Each of these holocrine glands
consists of multiple acini connected to a long
central duct, which secretes lipids comprised
mainly of wax and sterol esters. Under the effect
of chronic inflammation, they may develop
pouting, dropout, dilation, and epithelial
hyperkeratinization. Furthermore, changes in
the viscosity of lipid secretions due to structural
shifts of saturated hydrocarbons and protein
interaction may contribute to deranged tear
homeostasis [7, 8].
Microorganisms likely play a crucial role in
the development of blepharitis. Normal ocular
surface colonizers include Gram-positive
bacteria, especially coagulase-negative Staph
species (CoNS), Streptococcus, Corynebacterium,
and Propionibacterium acnes [9]. In the setting of
anterior blepharitis, CoNS are known to release
toxic by-products thus triggering an
inflammatory cascade. Acting upon the
posterior lid, some bacterial species are imbued
with lipases and esterases which cleave meibum
into free fatty acids and soaps. Moreover, loss of
polar lipids located between nonpolar and
aqueous components of the tear film may also
decrease lipid spreading. All these actions serve
to propagate further inflammation and
destabilize the tear film. Bacteria not only
colonize the superficial ocular surface, but
evidence suggests that they may be present
within deeper structures like the meibomian
orifices and ducts [10]. The pathophysiological
process has not been fully elucidated; however,
it can be postulated that deep intraductal
bacteria may contribute to meibum alterations
by acting upon them prior to formation of the
mature secretion.
Given the varied manifestations and
treatment recalcitrance of blepharitis, it is not
surprising that though many formulations have
been tried, they have demonstrated only
modest benefit. None are currently approved
by the food and drug administration (FDA) for
this indication.
CASE REPORT
Informed consent was obtained from the
patient for publication of this case report. A
78-year-old male with a past ocular history of
glaucoma and pseudophakia presented with
long-standing ocular dryness, grittiness,
periocular erythema, and eyelid crusting. On
facial inspection, nasal and facial telangiectasias
with flushing were evident. His topical medical
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regimen included one drop of latanoprost at
night in both eyes, one drop of brimonidine in
both eyes twice daily, and one drop of
dorzolamide/timolol in both eyes twice daily.
The patient endorsed utilization of a variety of
medicines and treatments to alleviate this
condition; however, they were of little benefit.
Failed therapies included topical prednisolone
acetate, loteprednol, azithromycin,
cyclosporine, and combination medicines such
as tobramycin/dexamethasone and neomycin/
polymyxin B/dexamethasone. Oral therapies
including doxycycline, and fish and flax seed
oils were also ineffective.
Slit lamp biomicroscopic examination
revealed bilateral anterior lid margin
erythema, crusting, and thickening. Lash
examination revealed some breakage with
scurf-like deposition. Inspection of the
posterior eyelids revealed inspissated
meibomian glands with capping and turbid
secretions. Further towards the posterior tarsal
area, dilated, engorged telangiectatic vessels
were present. The marginal lid erythema
extended not only to the tarsal plate, but also
to the inferior bulbar conjunctiva. Tear
break-up time was notably decreased and
corneae revealed inferior, bilateral punctate
epithelial erosions. A diagnosis of rosacea
blepharoconjunctivitis was made.
The patient was given a topical gel of 1%
PVP-I in a dimethylsulfoxide (DMSO) vehicle
that was prepared by a licensed compounding
pharmacy. The treatment was administered
twice daily and delivered by rubbing the gel
onto the lash line and eyelid. At the first
follow-up visit one week later, remarkable
improvements were noted. Most prominently,
much of the conjunctivitis, anterior lid
erythema, and thickening had reversed. The
patient was instructed to decrease the gel to
once daily, but to continue treatment for a total
of one month. At this second follow-up visit,
not only were the initial improvements
conserved, but the posterior lid margin vessels
and telangiectasias had begun to attenuate and
involute. Moreover, meibomian capping was no
longer present; secretions were less viscous and
tear break-up time normalized. Besides
occasional mild tingling at the application
site, the patient reported no other adverse
effects.
DISCUSSION
Blepharitis is often a recalcitrant, chronic ocular
condition with variable presentation.
Fortunately, sight-threatening manifestations
of this disease such as lid cicatrization,
malposition, trichiasis, and corneal infiltrates
are rare. Nonetheless, morbidity imparted in the
form of chalazia, rosacea, dry eye, contact lens
intolerance, and even anxiety is significant [11,
12]. The complex nature of blepharitis renders
curative treatment challenging as there are
currently no FDA-approved treatments. It has
been postulated that because of the
inflammatory and infectious natures of the
disease that controlling both of these variables
may form the bedrock for effective therapy [13].
PVP-I has been recognized as a safe, effective,
broad-spectrum, biocidal agent for many years
[14]. It is primarily utilized in ophthalmology
for antisepsis prior to procedures that place
patients at risk for endophthalmitis [14]. There
are a variety of other indications within
ophthalmology where low-dose (i.e., less than
10% w/w) PVP-I formulations have been shown
to be useful [15, 16]. Though incompletely
understood, it is likely its mechanism of
action relates to free iodide which poisons
electron transport, inhibits cellular respiration,
and destabilizes membranes. Ocular use of
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PVP-I has been highlighted previously by the
authors [17].
DMSO is an organic, polar, aprotic molecule
utilized as a pharmaceutical solvent for decades
[18]. The term aprotic refers to the lack of H?
ion available for proton donation in Brønsted
acid reactions. DMSO was first synthesized by
Alexander Saytzoff, a Russian chemist in 1867.
After remaining shrouded in obscurity for
almost a century, it was rediscovered in the
1950s for its ability to act as a ‘‘super solvent’’.
Notably, the DMSO chemical structure yields a
polar solvent with a high dielectric constant.
This property along with favorable
stereochemistry is thought to contribute to its
prodigious solvating ability [19].
DMSO is commonly produced as a
by-product of paper manufacture from lignin,
a fiber found in wood pulp. Its early utility
focused upon organ preservation studies
because of an unusual, dramatic ability to
depress the freezing point of water while
maintaining cellular viability [20]. The
development of DMSO as an active
pharmaceutical agent was halted in the late
1960s due to a perceived lack of ‘‘patentability’’
rendering commercialization a challenge. The
general lack of funding in conjunction with
increased vigilance by the FDA in light of the
thalidomide scares brought the development of
DMSO to a standstill. In 1978, the FDA finally
approved a 50% DMSO solution for
intravesicular delivery to treat interstitial
cystitis (RIMSO-50, NDA#017788, Mylan).
Since 1978, DMSO has been used in a variety
of FDA-approved drug products as an inactive
solvent and most recently in a topical
diclofenac formulation for knee-pain,
Pennsaid (NDA #020947, Nuvo Research Inc.).
The clinical utility of DMSO seems to derive
from two broad, imperfectly understood
mechanistic classes—radical scavenging and
penetration enhancement. DMSO is
considered a free radical trap. It is postulated
that free radical scavenging is responsible for
the abundant anecdotal reports of DMSO as a
cure for many skin, eye, and arthritic
conditions. Radical scavenging in general can
be viewed as an ‘‘anti- inflammatory’’ process
and many of the claims for DMSO utility are
based on some variation of suppressing the
inflammatory response [21].
There are four variables that influence
penetration of a solute through any given
membrane: (1) the diffusion coefficient
through the membrane, (2) the concentration
of the agent in the vehicle, (3) the partition
coefficient between the membrane and the
vehicle, and (4) the thickness of the
membrane barrier. Penetration agents are
designed to affect one or more of these
variables without causing permanent structural
or chemical modification of the physiological
barrier. DMSO is very well characterized as a
membrane penetration enhancement agent
[22]. The mechanism primarily involves
alteration of the diffusion and partition
coefficients at the membrane level. These
properties are due in part to favorable
reactions with membrane lipid head groups
and the production of more permeable
packing arrangements. DMSO is also
considered a small amphiphile and has a
propensity for rapid incorporation at the
membrane lipid–water interface. Studies have
highlighted the ability of DMSO to induce water
pores within lipid bilayers, thereby forming a
conduit for active molecules to enter cells [23].
As previously discussed, DMSO can also have a
profound effect on aqueous solubility of less
soluble agents and has been employed in a
variety of pharmaceutical preparations. These
interactions remain subject to molecular
weight, shape, and chemistry afforded by the
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solvent; however, the end result is the delivery
of a greater concentration of solute to the
target.
It is generally considered that ocular DMSO
utilization is so ubiquitous that it remains vastly
underreported. The non-peer-reviewed
literature and the Internet in general are rife
with anecdotal reports praising its utility and
safety in blepharitis, cataracts and for the
treatment of certain retinal diseases.
Fortunately, there also exists a robust body of
peer-reviewed literature that forms the bedrock
for its safe use in humans. In 1968, Gordon
published a seminal work on extended
utilization of DMSO in the human eye. He
reported on 157 eyes in which DMSO (7.5–66%)
was employed for various ophthalmic
indications [24]. These patients were followed
for a period of up to 19 months without the
observation of any ocular toxicity. At that time,
these were vital findings to the future of the
solvent as early animal testing had
demonstrated curious lenticular findings in
canines [24]. These findings were not
necessarily cataractous in nature, but
represented changes in translucency between
the lens nucleus and cortex along with myopic
shift. Other studies performed on monkeys,
guinea pigs, rabbits and later with cell culture
corroborated these observations [25, 26].In a
more encompassing report on human
utilization from the Second International
DMSO Symposium in Vienna, an astounding
9521 patients were followed and treated with
DMSO for up to 2.5 years [27]. There was not a
single instance of lens toxicity reported in any
of these study participants. In 1973, a landmark
report published in the Annals New York
Academy of Sciences further supported its safe
human use. Here, a topical DMSO aqueous
solution was administered daily to 65 patients
with up to 4–7 years of follow-up. No observable
toxicity was found outside of transient irritation
and occasional conjunctival erythema [28].
More recently, one case report of
DMSO-related lenticular pigmentary change
was noted in a woman being treated for
interstitial cystitis [29]. Her treatment was
with RIMSO-50, administered via multiple
bladder washouts. The pigmentary changes
were thought to be responsible for mild
hypermetropic shift; however, no change in
best corrected visual acuity was noted.
Other animal studies with DMSO have also
been performed yielding notable results. In
1977, a concentration-dependent exacerbation
of conjunctival inflammation was observed for
DMSO concentrations [90% (w/w, aqueous).
The authors found that 90% and 100% DMSO
worsened ocular inflammation, while doses
lower than 30% demonstrated
anti-inflammatory properties [30]. Other
studies conducted in 2010 and 2011 saw its
administration both subconjunctivally and
following trabeculotomy [31, 32]. A synopsis
of published DMSO ocular findings is detailed
in Table 1.
Our current understanding with respect to
preferential distribution of DMSO in the eye is
that uptake is most consistently found in the
cornea, aqueous, vitreous and sclera [33, 34].
Much of this data stems from sacrificial animal
studies performed in the 1960s. More recently, a
vitrification study for cryoprotective purposes
reconfirmed corneal uptake [35]. It is also
interesting to note that although animal
studies have endorsed lenticular alterations, to
our knowledge, DMSO does not accumulate in
the crystalline lens.
With respect to our patient in this case
report, it is not surprising that there appears to
be a demonstrable response in the setting of
rosacea blepharoconjunctivitis. The eyelid
structures represent therapeutic targets with
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architecture that is distinct in anatomy and
function [36]. Notably, it is upon the lid margin
skin where many of the microorganisms
responsible for causing devastating
post-surgical ocular infections reside [14]. Lid
margin bacteria not only populate and thrive
on the superficial lid tissues but may ensconce
within the deep eyelid or within dead layers of
skin cells, sweat glands, and hair follicles [37]. It
is logical, therefore, that successful therapy
should fundamentally offer both antisepsis
and lid penetration with significant
anti-inflammatory effect. This is the postulated
mechanism of action the authors endorse with
respect to the novel formulation discussed in
this manuscript.
It is important to note the shortcomings of
this case report. There was no utilization of a
blepharitis or eyelid vasculature/erythema
scoring scale, high-resolution external
photographs were not submitted, and there
was no scoring of corneal damage. Lastly, no
bacterial cultures of the lid margin or
conjunctival sac were taken to confirm
anti-septic effect.
CONCLUSIONS
Both DMSO and PVP-I have been known
separately in the medical and pharmaceutical
literature for decades. No one had previously
contemplated their combined use in
ophthalmic formulations until the current
report. We have shown possible success with
this novel formulation of low-dose PVP-I in a
proprietary DMSO gel/solvent system for a
difficult case of rosacea blepharoconjunctivitis.
This novel therapy may warrant further
investigation in randomized, controlled
clinical trials.
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